Merck KGaA Shares Drop After Canceled Late-Stage Cancer Drug Study
By David Sachs
Merck KGaA shares fell in early trading after the firm discontinued a late-stage trial for a cancer drug.
At 0729 GMT, Merck shares were down 10.1% at EUR150.25 after falling as low as EUR149.05.
The German life-sciences company said late Monday that it canceled the Phase 3 trial of xevinapant, meant to treat a type of head and neck cancer that cannot be surgically removed. The decision came after an independent committee found that the drug was unlikely to achieve its main goal of extending patients' lives without the cancer worsening, Merck said.
Investors can expect an impairment of around 60 million euros ($64.4 million) from the termination, Jefferies analysts said in a note. The outcome could cause traders to question the company's research and development capabilities, the analysts said, adding that the recent evobrutinib failure compounds the discontinued study.
Based on the data, Merck also stopped another Phase 3 trial known as X-Ray Vision, which was testing xevinapant combined with radiotherapy in patients who had surgery for advanced head and neck cancer.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
June 25, 2024 03:54 ET (07:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks
-
What Is a Stock Split?
-
10 Best Value Stocks to Buy for the Long Term